Measuring patient-reported physical functioning and fatigue in myelodysplastic syndromes using a modular approach based on EORTC QLQ-C30

[1] Prebet T(2016)Trends in clinical investigation for myelodysplastic syndromes Clin Lymphoma Myeloma Leuk 16 S57-S63

[2] Zeidan A(2015)Patient-reported outcomes in drug development for hematology Hematology Am Soc Hematol Educ Program 2015 496-500

[3] Acquadro C(2017)Patient-reported outcomes in hematology: Is it time to focus more on them in clinical trials and hematology practice? Blood. 130 859-866

[4] Regnault A(2016)Focusing on core patient-reported outcomes in cancer clinical trials: Symptomatic adverse events, physical function, and disease-related symptoms Clin Cancer Res 22 1553-1558

[5] Efficace F(2016)Focusing on Core patient-reported outcomes in Cancer clinical trials-response Clin Cancer Res 22 5618-73

[6] Gaidano G(2016)Patient-reported outcomes in Cancer clinical trials: Measuring symptomatic adverse events with the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) Am Soc Clin Oncol Educ Book 35 67-623

[7] Lo-Coco F(2018)Patient-reported outcomes version of the common terminology criteria for adverse events: Methods for item selection in industry-sponsored oncology clinical trials Clin Trials 15 616-823

[8] Kluetz PG(2019)A pragmatic patient-reported outcome strategy for rare disease clinical trials: Application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia J Patient Rep Outcomes 3 35-655

[9] Slagle A(2020)Consistency matters: Measurement invariance of the EORTC QLQ-C30 questionnaire in patients with hematologic malignancies Qual Life Res 29 815-210

[10] Papadopoulos EJ(2017)Measuring what matters to rare disease patients - reflections on the work by the IRDiRC taskforce on patient-centered outcome measures Orphanet J Rare Dis 12 171-585

[1] Prebet T(2016)Trends in clinical investigation for myelodysplastic syndromes Clin Lymphoma Myeloma Leuk 16 S57-S63

[2] Zeidan A(2015)Patient-reported outcomes in drug development for hematology Hematology Am Soc Hematol Educ Program 2015 496-500

[3] Acquadro C(2017)Patient-reported outcomes in hematology: Is it time to focus more on them in clinical trials and hematology practice? Blood. 130 859-866

[4] Regnault A(2016)Focusing on core patient-reported outcomes in cancer clinical trials: Symptomatic adverse events, physical function, and disease-related symptoms Clin Cancer Res 22 1553-1558

[5] Efficace F(2016)Focusing on Core patient-reported outcomes in Cancer clinical trials-response Clin Cancer Res 22 5618-73

[6] Gaidano G(2016)Patient-reported outcomes in Cancer clinical trials: Measuring symptomatic adverse events with the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) Am Soc Clin Oncol Educ Book 35 67-623

[7] Lo-Coco F(2018)Patient-reported outcomes version of the common terminology criteria for adverse events: Methods for item selection in industry-sponsored oncology clinical trials Clin Trials 15 616-823

[8] Kluetz PG(2019)A pragmatic patient-reported outcome strategy for rare disease clinical trials: Application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia J Patient Rep Outcomes 3 35-655

[9] Slagle A(2020)Consistency matters: Measurement invariance of the EORTC QLQ-C30 questionnaire in patients with hematologic malignancies Qual Life Res 29 815-210

[10] Papadopoulos EJ(2017)Measuring what matters to rare disease patients - reflections on the work by the IRDiRC taskforce on patient-centered outcome measures Orphanet J Rare Dis 12 171-585